PL410454A1 - Method for identification of response of a patient with psoriasis disease to treatment with genistein, molecular test and application of gene expressions for the in vitro detection of psoriasis - Google Patents
Method for identification of response of a patient with psoriasis disease to treatment with genistein, molecular test and application of gene expressions for the in vitro detection of psoriasisInfo
- Publication number
- PL410454A1 PL410454A1 PL410454A PL41045414A PL410454A1 PL 410454 A1 PL410454 A1 PL 410454A1 PL 410454 A PL410454 A PL 410454A PL 41045414 A PL41045414 A PL 41045414A PL 410454 A1 PL410454 A1 PL 410454A1
- Authority
- PL
- Poland
- Prior art keywords
- psoriasis
- patient
- response
- genistein
- treatment
- Prior art date
Links
- 201000004681 Psoriasis Diseases 0.000 title abstract 5
- 230000014509 gene expression Effects 0.000 title abstract 3
- 229940045109 genistein Drugs 0.000 title abstract 3
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 title abstract 3
- 235000006539 genistein Nutrition 0.000 title abstract 3
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 title abstract 3
- 238000001514 detection method Methods 0.000 title abstract 2
- 238000000338 in vitro Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- -1 PI3 Proteins 0.000 abstract 2
- 102100021641 Acetyl-CoA carboxylase 2 Human genes 0.000 abstract 1
- 102100034542 Acyl-CoA (8-3)-desaturase Human genes 0.000 abstract 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 abstract 1
- 102100024491 Cdc42 effector protein 5 Human genes 0.000 abstract 1
- 108010009306 Forkhead Box Protein O1 Proteins 0.000 abstract 1
- 102000009561 Forkhead Box Protein O1 Human genes 0.000 abstract 1
- 102100021084 Forkhead box protein C1 Human genes 0.000 abstract 1
- 102100037156 Gap junction beta-2 protein Human genes 0.000 abstract 1
- 102100028896 Heterogeneous nuclear ribonucleoprotein Q Human genes 0.000 abstract 1
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 abstract 1
- 101000677540 Homo sapiens Acetyl-CoA carboxylase 2 Proteins 0.000 abstract 1
- 101000848239 Homo sapiens Acyl-CoA (8-3)-desaturase Proteins 0.000 abstract 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 abstract 1
- 101000762416 Homo sapiens Cdc42 effector protein 5 Proteins 0.000 abstract 1
- 101000818310 Homo sapiens Forkhead box protein C1 Proteins 0.000 abstract 1
- 101000954092 Homo sapiens Gap junction beta-2 protein Proteins 0.000 abstract 1
- 101000839069 Homo sapiens Heterogeneous nuclear ribonucleoprotein Q Proteins 0.000 abstract 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 abstract 1
- 101001056445 Homo sapiens Keratin, type II cytoskeletal 6B Proteins 0.000 abstract 1
- 101000616810 Homo sapiens MAL-like protein Proteins 0.000 abstract 1
- 101000955254 Homo sapiens Multiple epidermal growth factor-like domains protein 9 Proteins 0.000 abstract 1
- 101001000109 Homo sapiens Myosin-10 Proteins 0.000 abstract 1
- 101000612397 Homo sapiens Prenylcysteine oxidase 1 Proteins 0.000 abstract 1
- 101000666607 Homo sapiens Rho-related BTB domain-containing protein 3 Proteins 0.000 abstract 1
- 101000879761 Homo sapiens Sarcospan Proteins 0.000 abstract 1
- 101000701815 Homo sapiens Spermidine synthase Proteins 0.000 abstract 1
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 abstract 1
- 101000633976 Homo sapiens Tuftelin Proteins 0.000 abstract 1
- 101000587313 Homo sapiens Tyrosine-protein kinase Srms Proteins 0.000 abstract 1
- 101000607984 Homo sapiens Uronyl 2-sulfotransferase Proteins 0.000 abstract 1
- 101000864773 Homo sapiens Vesicle transport protein SFT2B Proteins 0.000 abstract 1
- 101000818737 Homo sapiens Zinc finger protein 12 Proteins 0.000 abstract 1
- 101000915632 Homo sapiens Zinc finger protein 483 Proteins 0.000 abstract 1
- 101000785613 Homo sapiens Zinc finger protein 652 Proteins 0.000 abstract 1
- 102100025655 Keratin, type II cytoskeletal 6B Human genes 0.000 abstract 1
- 102100021832 MAL-like protein Human genes 0.000 abstract 1
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 abstract 1
- 102100038989 Multiple epidermal growth factor-like domains protein 9 Human genes 0.000 abstract 1
- 102100036640 Myosin-10 Human genes 0.000 abstract 1
- 102100041004 Prenylcysteine oxidase 1 Human genes 0.000 abstract 1
- 102100038342 Rho-related BTB domain-containing protein 3 Human genes 0.000 abstract 1
- 102100027611 Rho-related GTP-binding protein RhoB Human genes 0.000 abstract 1
- 101150054980 Rhob gene Proteins 0.000 abstract 1
- 102100037329 Sarcospan Human genes 0.000 abstract 1
- 102100026966 Thrombomodulin Human genes 0.000 abstract 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 abstract 1
- 102100029243 Tuftelin Human genes 0.000 abstract 1
- 102100029654 Tyrosine-protein kinase Srms Human genes 0.000 abstract 1
- 102100039838 Uronyl 2-sulfotransferase Human genes 0.000 abstract 1
- 102100030062 Vesicle transport protein SFT2B Human genes 0.000 abstract 1
- 102100021058 Zinc finger protein 12 Human genes 0.000 abstract 1
- 102100029035 Zinc finger protein 483 Human genes 0.000 abstract 1
- 102100026453 Zinc finger protein 652 Human genes 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Przedmiotem wynalazku jest sposób identyfikowania molekularnej odpowiedzi pacjenta chorego na łuszczycę na leczenie genisteiną, gdzie określa się w próbce biologicznej pobranej od pacjenta poziom ekspresji 30 genów przedstawionych poniżej: EZH2, CDC42EP5, F12, GJB2, KRT6B, MALL, PI3, SFT2D2, SRM, SYNCRIP, THBD, ACACB, CAT, FADS1, FASN, FOXC1, FOXO1, JUN, MEGF9, MYH10, PCYOX1 RHOB, RHOBTB3, SSPN, TIMP3, TUFT1, UST, ZNF12, ZNF483, ZNF652. Ujawniono także molekularny test do wykrywania odpowiedzi pacjenta chorego na łuszczycę na leczenie genisteiną oraz zastosowanie ekspresji 30 genów do wykrywania in vitro łuszczycy u pacjenta.The subject of the invention is a method of identifying the molecular response of a patient suffering from psoriasis to genistein treatment, where the level of expression of 30 genes specified in the biological sample taken from the patient is determined: EZH2, CDC42EP5, F12, GJB2, KRT6B, MALL, PI3, SFT2D2, SRM, SYNCRIP , THBD, ACACB, CAT, FADS1, FASN, FOXC1, FOXO1, JUN, MEGF9, MYH10, PCYOX1 RHOB, RHOBTB3, SSPN, TIMP3, TUFT1, UST, ZNF12, ZNF483, ZNF652. Also disclosed is a molecular test for detecting a patient's psoriasis response to genistein treatment and the use of gene expression for in vitro detection of psoriasis in a patient.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL410454A PL410454A1 (en) | 2014-12-08 | 2014-12-08 | Method for identification of response of a patient with psoriasis disease to treatment with genistein, molecular test and application of gene expressions for the in vitro detection of psoriasis |
| PCT/PL2015/000198 WO2016093718A1 (en) | 2014-12-08 | 2015-12-08 | Methods for identifying response of patients suffering from psoriasis to genistein treatment and molecular assays therefor |
| EP15828396.0A EP3230470A1 (en) | 2014-12-08 | 2015-12-08 | Methods for identifying response of patients suffering from psoriasis to genistein treatment and molecular assays therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL410454A PL410454A1 (en) | 2014-12-08 | 2014-12-08 | Method for identification of response of a patient with psoriasis disease to treatment with genistein, molecular test and application of gene expressions for the in vitro detection of psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL410454A1 true PL410454A1 (en) | 2016-06-20 |
Family
ID=55221478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL410454A PL410454A1 (en) | 2014-12-08 | 2014-12-08 | Method for identification of response of a patient with psoriasis disease to treatment with genistein, molecular test and application of gene expressions for the in vitro detection of psoriasis |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3230470A1 (en) |
| PL (1) | PL410454A1 (en) |
| WO (1) | WO2016093718A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101933694B1 (en) | 2017-06-30 | 2018-12-28 | 동국대학교 산학협력단 | Diagnostic kit comprising biomarkers for genistein exposure diagnosis |
| CN110004220A (en) * | 2019-01-11 | 2019-07-12 | 北京蛋白质组研究中心 | A kind of psoriasis blood serum designated object and its application |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020037538A1 (en) * | 2000-05-09 | 2002-03-28 | Trepicchio William L. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis |
| EP1977007A4 (en) * | 2005-12-28 | 2009-11-11 | Centocor Ortho Biotech Inc | Markers and methods for assessing and treating psoriasis and related disorders |
| EP2212442A1 (en) * | 2007-10-26 | 2010-08-04 | Galderma Research & Development | Non-invasive method to perform skin inflammatory disease pharmaco-genomic studies and diagnosis method thereof |
-
2014
- 2014-12-08 PL PL410454A patent/PL410454A1/en unknown
-
2015
- 2015-12-08 EP EP15828396.0A patent/EP3230470A1/en not_active Withdrawn
- 2015-12-08 WO PCT/PL2015/000198 patent/WO2016093718A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3230470A1 (en) | 2017-10-18 |
| WO2016093718A1 (en) | 2016-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125190T1 (en) | USE OF GROUPS OF FGFR MUTANT GENES TO DETERMINE WHETHER CANCER PATIENTS WILL RESPOND TO TREATMENT WITH FGFR INHIBITORS | |
| MX2020001156A (en) | METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS. | |
| BR112014031365A2 (en) | methods of detecting disease or conditions | |
| AR099856A1 (en) | METHODS TO DIAGNOSE AND TREAT INFLAMMED INTESTINE DISEASE | |
| BR112013006764A2 (en) | method for assessing a patient, kit, computer readable medium, method for assessing a treatment, method for assessing a patient's risk, method for monitoring, method for diagnosing, testing system, method for classifying or grouping a population of individuals, method for assessing a surrogate outcome, method for treating, use of at least one biomarker, use of an agent | |
| BR112015023120A2 (en) | method for identifying an individual with a disease or dysfunction, method for predicting the responsiveness of an individual with a disease or dysfunction, method for determining the likelihood that an individual with a disease or dysfunction will exhibit benefit from treatment, method for selecting a therapy, Uses of a pd-11 Axis Binding Antagonist, Assay to Identify an Individual with a Disease, Diagnostic Kit, Method to Evaluate a Treatment Response, and Method to Monitor the Response of a Treated Individual | |
| BR112018069849A2 (en) | kit, device and method for the detection of early pancreatic cancer or pancreatic cancer precursor lesion | |
| AR098155A1 (en) | METHODS TO DIAGNOSTIC AND TREAT EOSYNOPHYL DISORDERS | |
| EP4282405A3 (en) | Detection of cancer biomarkers using nanoparticles | |
| BR112015023699A2 (en) | method of determining a level of expression of a fibrotic pulmonary disease marker protein, method of determining whether an individual has or is at risk of developing fibrotic pulmonary disease, method of determining whether a patient of fibrotic pulmonary disease is at risk of progression of fibrotic pulmonary disease, method of determining fibrotic pulmonary disease activity in a patient, and method of treating fibrotic pulmonary disease in an individual in need thereof | |
| EP4276190A3 (en) | Methods for the diagnosis of bacterial vaginosis | |
| WO2018007872A9 (en) | Biomarkers for inflammatory bowel disease | |
| JOP20190199B1 (en) | Use of biological factors to identify cancer patients who will respond to PRMT5 inhibitor therapy | |
| MX2018014047A (en) | STROMAL GENES SIGNATURES FOR DIAGNOSIS AND USE IN IMMUNOTHERAPY. | |
| BRPI0815448A2 (en) | "QUICK EVALUATION OF TOP RESPIRATORY CONDITIONS" | |
| BR112016028838A2 (en) | antibodies, nucleic acid, host cell, antibody production method, immunoconjugate, pharmaceutical formulation, methods of detecting human lgr5 in a biological sample, detecting a cancer, identifying a cancer patient, selecting a patient with cancer for treatment with an immunoconjugate and treatment of a cancer patient | |
| SG10201806729VA (en) | Novel assay to detect human periostin | |
| MX2022000628A (en) | DETECTION OF GENOMIC SEQUENCES USING COMBINATIONS OF PROBES, PROBE MOLECULES AND ARRAYS COMPRISING THE PROBES FOR THE SPECIFIC DETECTION OF ORGANISMS. | |
| BR112022015578A2 (en) | METHOD FOR IDENTIFYING ONE OR MORE LIPIDS IN A SAMPLE, DEVICE FOR IDENTIFYING ONE OR MORE LIPIDS IN A SAMPLE, KIT FOR IDENTIFYING ONE OR MORE LIPIDS IN A SAMPLE AND METHOD FOR DETECTING THE PRESENCE OR ABSENCE OF ONE OR MORE DISEASES OR MEDICAL CONDITIONS IN A SUBJECT | |
| PL410454A1 (en) | Method for identification of response of a patient with psoriasis disease to treatment with genistein, molecular test and application of gene expressions for the in vitro detection of psoriasis | |
| Gopu et al. | An accurate aging clock developed from the largest dataset of microbial and human gene expression reveals molecular mechanisms of aging | |
| ITMI20120865A1 (en) | BIOMARCERS FOR PATHOLOGIES OF THE CENTRAL NERVOUS SYSTEM | |
| BR112019005179A2 (en) | method and kit for analyzing a sample | |
| BR102015015096A2 (en) | in vitro detection method of thyroid cancer in a patient, in vitro method of differentiating thyroid cancer from normal thyroid tissue or benign thyroid lesions, use of a gene pool, method of obtaining data for treatment management cancer test, laboratory kit, and device for classifying a biological sample of thyroid gland as malignant or benign | |
| SG11201806907XA (en) | Obesity risk diagnosis kit and method for analyzing risk of obesity onset |